Genentech Wants Other Firms' Compounds For Mass Pediatric Cancer Screening

Master protocol for Phase I/II screening trial could make development more efficient, but concerns about regulatory obligations, lack of registrational intent and infrastructure complexity – as well as firms' willingness to share – may be hurdles to participation.